Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Abstract

Visceral and hepatic adiposities have been associated with both cardiovascular and liver disease and are of concern in HIV-infected persons in the modern era of combination antiretroviral therapy (ART). The development of therapeutic targets to reduce visceral and hepatic adiposities in HIV-infected persons has been slow, because of early reports that attributed the excess adiposity to specific antiretroviral drugs. Visceral adiposity was initially thought to occur as part of a protease inhibitor-induced "HIV-associated lipodystrophy syndrome." Subsequent studies show that visceral adiposity is likely a result of effective ART, recovery of health, and the normal aging process. Visceral adiposity is an established risk factor for hepatic adiposity. Identifying drug targets for non-alcoholic fatty liver disease is under active investigation. The present review summarizes the recent literature on the pathogenesis of visceral and hepatic adiposities in HIV-infected persons, current therapeutic strategies, and novel interventions in HIV-infected and uninfected persons.

• Authors: Phyllis C Tien
• Journal: Current atherosclerosis reports (Curr Atheroscler Rep) Vol. 17 Issue 12 Pg. 73 (Dec 2015) ISSN: 1534-6242 [Electronic] United States
• PMID: 26493063 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Topics

• Adiposity
• Animals
• Cardiovascular Diseases (complications)
• HIV-Associated Lipodystrophy Syndrome (drug therapy)
• Humans
• Non-alcoholic Fatty Liver Disease (drug therapy)
• Risk Factors